Insmed Q3 GAAP EPS $(1.11) Beats $(1.12) Estimate, Sales $79.07M Miss $79.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed reported Q3 GAAP EPS of $(1.11), beating the estimate of $(1.12) by 0.89%. However, the company's sales of $79.07M missed the estimate of $79.13M by 0.07%. This represents a 1.83% decrease in losses and a 16.75% increase in sales compared to the same period last year.
October 26, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Insmed's Q3 earnings beat estimates but sales fell short. This could have mixed effects on the stock.
Insmed's earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100